Angus Wilfong

TL;DR: The findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy.

TL;DR: Cannabidiol is added as a possible treatment for febrile infection-related epilepsy syndrome who had not responded to antiepileptic drugs or other therapies who were given cannabadiol on emergency or expanded investigational protocols in either the acute or chronic phase of illness.

TL;DR: Zonisamide is a second-generation antiepileptic drug that has broad-spectrum efficacy, a favorable side-effect profile and simpler dosing than earlier drugs, and should be considered as an adjunctive therapeutic for a wide-range of generalized epilepsies.

TL;DR: This large series of patients confirms the safety and efficacy of MRgLITT for pediatric HH and describes morphological considerations that predict success, suggesting that complete ablation of the lesion is not necessary, and that the focus should be on appropriate disconnection of the epileptogenic network.

TL;DR: The results suggest that both the ERK and mTOR pathways are dysregulated in FCD and TS; however, the signaling alterations are different for FCD I as compared to FCD II and TS.